DETROL Drug Patent Profile

Which patents cover Detrol, and when can generic versions of Detrol launch?

Detrol is a drug marketed by Upjohn and is included in two NDAs.

The generic ingredient in DETROL is tolterodine tartrate. There is one drug master file entry for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the tolterodine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Detrol

A generic version of DETROL was approved as tolterodine tartrate by IVAX SUB TEVA PHARMS on February 23^rd, 2015.

Summary for DETROL

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	16
Patent Applications:	531
Drug Prices:	Drug price information for DETROL
What excipients (inactive ingredients) are in DETROL?	DETROL excipients list
DailyMed Link:	DETROL at DailyMed

See drug prices for DETROL

Recent Clinical Trials for DETROL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	Phase 4
Astellas Scientific & Medical Affairs, Inc.
Astellas Pharma Global Development, Inc.	Phase 4

See all DETROL clinical trials

Pharmacology for DETROL

Drug Class	Cholinergic Muscarinic Antagonist
Mechanism of Action	Cholinergic Muscarinic Antagonists

US Patents and Regulatory Information for DETROL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-001	Mar 25, 1998	AB	RX	Yes	No
Upjohn	DETROL LA	tolterodine tartrate	CAPSULE, EXTENDED RELEASE;ORAL	021228-002	Dec 22, 2000	AB	RX	Yes	Yes
Upjohn	DETROL	tolterodine tartrate	TABLET;ORAL	020771-002	Mar 25, 1998	AB	RX	Yes	Yes
Upjohn	DETROL LA	tolterodine tartrate	CAPSULE, EXTENDED RELEASE;ORAL	021228-001	Dec 22, 2000	AB	RX	Yes	No

International Patents for DETROL

See the table below for patents covering DETROL around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	65990
Australia	2932989
Australia	635493
Canada	1340223	3,3-DIPHENYLPROPYLAMINES ET LEURS COMPOSITIONS PHARMACEUTIQUES; UTILISATION DANS DES SYSTEMES CHOLINERGIQUES (3,3-DIPHENYLPROPYL AMINES AND PHARMACEUTICAL COMPOSITIONS AND CHOLINERGIC USES THEREOF)

Supplementary Protection Certificates for DETROL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0325571	SPC/GB98/027	United Kingdom		PRODUCT NAME: TOLTERODINE OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: SE 13475 19970905; SE 13476 19970905; UK 00032/0222 19980203; UK 00032/0223 19980203
0325571	1998C0031	Belgium		PRODUCT NAME: TOLTERODINI-L-TARTRAS (=TOLTERODINUM); NATL REGISTRATION NO/DATE: 277 IS 301 F 3 19980309; FIRST REGISTRATION: SE 13475 19970905
0325571	C980020	Netherlands		PRODUCT NAME: TOLTERODINE, DESGEWENST IN DE VORM VAN EEN ZOUT MET EEN FYSIOLO GISCH ACCEPTABEL ZUUR, IN HET BIJZONDER TOLTERODINE L-TARTRAAT; NAT. REGISTRATION NO/DATE: RVG 22148, RVG 22149 19980217; FIRST REGISTRATION: SE 13475, 13476 19970905
0325571	21/1998	Austria		PRODUCT NAME: TOLTERODIN, SEINE SALZE, RACEMATE UND ENANTIOMERE; NAT. REGISTRATION NO/DATE: 1-22389 UND 1-22390 19980210; FIRST REGISTRATION: SE 13475 UND 13476 19970905

Last updated: July 27, 2026

DEtrol (tolterodine) market dynamics and financial trajectory: brand sales, channel structure, payer pressure, and generic erosion

Executive summary: Detrol (tolterodine) sales have structurally declined since generic entry. The market moved from prescription fill growth to share capture by generic tolterodine IR/ER and combination generics where applicable, with payer formularies tightening around preferred antimuscarinics for overactive bladder (OAB). Financial trajectory is driven by (1) persistent generic competition, (2) OAB prescribing shifts toward agents with differentiated tolerability profiles, and (3) the continued replacement of older antimuscarinic brands with multi-source generics and newer therapeutic classes.

How have DETROL sales trended since generic entry?

Detrol is a tolterodine brand for overactive bladder. Tolterodine’s brand-to-generic transition is the primary driver of its long-run revenue profile: once generics gained market access in the US and other markets, brand pricing power and share sustainability weakened quickly.

Featured snippet answer: Detrol’s financial trajectory is dominated by sustained post-generic decline rather than recurring growth cycles.

What typically happens to revenue in antimuscarinic OAB after generic substitution

OAB antimuscarinics usually show a similar pattern:

• Brand volumes peak near launch and early labeling expansion.
• Price pressure escalates once authorized or non-authorized generics enter.
• Payer step edits favor lower WAC-cost multisource drugs.
• Prescribers shift to other antimuscarinics or beta-3 agonists when adverse events (dry mouth, constipation, cognitive concerns in vulnerable populations) drive switching.

Which DETROL products matter: Detrol vs Detrol LA and how does that affect market share?

Detrol in practice refers to tolterodine immediate-release (IR) and Detrol LA (extended-release). Market dynamics differ by formulation because payer formularies and patient persistence vary by dosing frequency and side-effect exposure.

Key point: Even when one formulation holds up longer, the class generally declines together as generics expand and preferred formularies shift.

Formulation-driven dynamics

• IR (Detrol): More frequent dosing can create adherence friction. When generics proliferate, IR often becomes a low-cost backbone option.
• ER (Detrol LA): Often selected for convenience and smoother symptom control. ER generics tend to capture brand replacement once they are available at discount price points.

What competitive forces shape DETROL’s OAB market dynamics?

Detrol competes in a crowded OAB category where formularies are influenced by tolerability, adherence, and total medical costs. Antimuscarinics face class-wide substitution pressure and “therapeutic inertia” breakpoints created by new entrants.

Primary competitors and substitution vectors

1. Other antimuscarinics (generics and brands): oxybutynin products, solifenacin, fesoterodine, darifenacin, trospium and generics across these.
2. Newer mechanisms: beta-3 adrenergic agonists (often preferred for reduced anticholinergic adverse events), and in some geographies, OAB-focused combination strategies.
3. Non-pharmacologic and procedural pathways: third-line therapies and specialist management in refractory patients can reduce chronic prescription churn for any single drug.

How do payer formularies and step therapy affect DETROL profitability?

Payer behavior drives two outcomes: (1) volume migration away from non-preferred brands to low-cost multisource options and (2) reduced ability to sustain premium pricing.

Mechanisms of payer pressure that hit antimuscarinics

• Formulary tiering: Detrol products typically fall from preferred to non-preferred tiers once generics dominate.
• Step edits: patients may need trials of preferred antimuscarinics or beta-3 agonists before Detrol is authorized.
• Quantity limits and persistence rules: tolerability can lead to therapy discontinuation, impacting net realized revenue.

What is the financial trajectory for DETROL in the US: revenue, margin profile, and channel economics?

Detrol is a mature, single-API OAB product. Its US financial trajectory is best characterized as:

• Prior to generic entry: meaningful brand margins with premium pricing and market-building spend.
• Post-generic entry: erosion in gross-to-net via rebates and discounts, followed by declining net sales as multisource prescriptions substitute.

Featured snippet answer: Post-entry economics compress margins due to discounting and a shift from brand mix to generic mix.

Channel economics: why generic substitution accelerates net sales decline

Once Detrol is multi-source, pharmacy benefit managers negotiate based on:

• lowest effective cost,
• class-level interchangeability,
• formulary tier placement,
• and rebate dynamics that penalize non-preferred SKUs.

That translates into sustained pressure on brand realized prices even if some patients remain on Detrol.

How does DETROL compare with other OAB therapies on market dynamics?

Detrol’s long-run competitive posture depends on how prescribers rank tolerability and efficacy against alternatives.

Positioning in the OAB market

• Clinical differentiation: Detrol is an established antimuscarinic. It competes on symptom control but is weighed against side-effect burden common to antimuscarinics.
• Market differentiation: differentiation narrows as generics reduce price-led differentiation and beta-3 agonists capture “tolerability preference” cohorts.

What manufacturing and supply chain factors influence DETROL availability and pricing?

Mature single-API products typically face:

• stable supply for generic entrants,
• periodic manufacturing disruptions that can temporarily move prices,
• and heightened scrutiny of quality and bioequivalence that can cause launch friction for new generics.

These effects are usually secondary to payer and patent-driven substitution, but they can create short bursts in pricing power among remaining suppliers.

When did DETROL face major exclusivity and patent/market-access inflection points?

Detrol’s economic inflection is primarily driven by generic market access and the expiration of the relevant exclusivity and patent estate for tolterodine formulations and uses.

Featured snippet answer: The dominant inflection is the transition from brand exclusivity to generic availability, which leads to multi-year sales declines.

How to interpret “financial trajectory” for a mature OAB brand

In practice, for older antimuscarinic brands:

• the first post-exclusivity year shows the steepest share loss,
• subsequent years show a flatter decline as the generic market saturates,
• and volumes then track population growth and OAB diagnosis rates rather than therapy-specific brand marketing.

What generic entry risks exist for DETROL, and how do they influence market share?

Generic entry risks are tied to:

• ANDA approval readiness,
• bioequivalence strategy for ER vs IR,
• packaging and distribution scale,
• and interchangeability under payer and pharmacy formularies.

Once multiple ANDAs exist, the brand is economically exposed regardless of individual generic applicant strength.

What FDA pathway dynamics matter for DETROL generics and formulation changes?

Tolterodine products rely on standard generics pathways once patents and exclusivity expire.

Key regulatory realities affecting competition

• For ER products, release characteristics and BE studies make the formulation an engineering challenge.
• For IR, BE is generally less complex than ER, so competitive entry can be faster after legal clearance.

Which companies have commercialized tolterodine generics that displaced DETROL?

Brand displacement is driven by generic manufacturers across the US multi-source environment. The market structure generally includes:

• large generic houses with broad distribution,
• regional and specialty generics,
• and pharmacy-controlled wholesalers negotiating based on lowest net cost.

What litigation and settlement dynamics have affected DETROL competition?

Settlement dynamics can determine:

• whether the brand faces “at-risk” launches,
• whether certain entrants are delayed by stipulated launch dates,
• and whether authorized generics (AGs) take share.

For Detrol, any specific litigation or settlement impact depends on the identity of the relevant patent(s) and the challenged formulations or methods. Without a defined patent and case record in this prompt context, the litigation-driven impact cannot be mapped precisely into a time-stamped competitive scenario.

How strong is the competitive moat for DETROL after patent expiry?

For mature tolterodine products, the moat is limited after exclusivity expiration:

• the API is off-patent,
• formulations tend to become quickly multisource,
• and payer systems normalize antimuscarinic selection by cost and coverage.

Featured snippet answer: The post-expiry “moat” is primarily brand legacy and prescriber familiarity, not enforceable IP.

Global market dynamics for DETROL: how do geography and reimbursement alter trajectory?

Detrol’s financial profile outside the US depends on:

• patent and exclusivity periods by jurisdiction,
• local generic penetration speed,
• national reimbursement rules and tender mechanisms,
• and OAB therapeutic mix shifts.

In Europe and other single-payer systems, tender pricing often compresses branded revenue earlier once generics qualify.

Key Takeaways

• Detrol’s financial trajectory is primarily a post-generic sales erosion story, driven by payer cost controls and multi-source substitution.
• IR vs ER format differences affect persistence and share within the class, but they do not reverse structural decline once generics dominate.
• Competitive pressure in OAB increasingly favors therapies selected for tolerability and ease of use, accelerating displacement even within the antimuscarinic class.
• For business planning, expected Detrol value is limited to residual share, contract pricing, and remaining non-interchangeable patient segments.

FAQs

1. Why do antimuscarinic OAB brands like Detrol decline faster after generics enter?
   Because payer tiering, rebate pressure, and interchangeability drive rapid volume migration to the lowest net cost.

2. Does Detrol LA usually retain more share than Detrol IR after generic competition?
   Often ER products retain some preference due to dosing convenience, but both IR and ER typically converge toward low-cost multisource dynamics.

3. How do beta-3 agonists change Detrol’s competitive outlook?
   They can capture patient cohorts concerned with anticholinergic side effects, reducing the addressable pool for tolterodine over time.

4. What factors determine how quickly Detrol generics gain market share?
   Launch readiness, contract coverage, pharmacy distribution scale, and BE success for ER formulations.

5. Can authorized generics slow Detrol’s revenue decline?
   They can reduce brand exclusivity gains by replacing brand share with a branded-labeled generic channel, but they do not restore long-run brand profitability.

References

1. FDA. “Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).” U.S. Food and Drug Administration.
2. FDA. “Drug Competition Action Plan.” U.S. Food and Drug Administration.
3. European Medicines Agency. “EPAR: Overview and history of marketing authorization for tolterodine-containing products.” European Medicines Agency.
4. IMS Institute / IQVIA. OAB market and reimbursement analyses (industry reports).

DrugChatter Q&A for DETROL

Can i get detrol without a prescription?
Detrol generic?